Previous 10 | Next 10 |
home / stock / cqpty / cqpty news
CollPlant Biotechnologies Reports First Quarter 2021 Financial Results with Record Revenues of $14.5 Million Operating income for Q1 2021 increased to $10 million Strong balance sheet with $49.7 million cash position PR Newswire REHOVOT, Israel , May 27, 20...
CollPlant Announces Uplisting to the Nasdaq Global Market® and Transition to Trading of Ordinary Shares Instead of ADSs - Ordinary shares to trade on Nasdaq Global Market effective June 4, 2021 - ADSs to be mandatorily cancelled and exchanged into ordinary shares PR...
CollPlant Appoints Additive Manufacturing Executive, Hugh Evans to Its Board of Directors PR Newswire REHOVOT, Israel , March 29, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced the appointmen...
CollPlant Biotechnologies Reports Year End Financial Results for Fiscal Year 2020 - Revenues increased by 165% from $2.3 million to $6.1 million - $103 M-plus strategic agreement entered into with Allergan Aesthetics, an AbbVie company, for rhCollagen to be used in dermal an...
CollPlant To Present at the H.C. Wainwright Global Life Sciences Conference PR Newswire REHOVOT, Israel , March 4, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced that Mr. Yehiel Tal , Chi...
Termination of Licensing Agreement for Bioprinting of Scaffolds for Lung Transplants PR Newswire REHOVOT, Israel , Feb. 25, 2021 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN) a regenerative and aesthetics medicine company, today announced that on ...
CollPlant Issues Letter to Shareholders Expansion of collaboration with United Therapeutics to cover a second lifesaving organ, human kidneys, in addition to lungs Development and commercialization agreement with Allergan Aesthetics, an AbbVie company, for rhCollagen to be u...
CollPlant Announces Development and Global Commercialization Agreement with Allergan Aesthetics, an AbbVie company, for rhCollagen in Dermal and Soft Tissue Filler Products Potential to receive up to $103 million in upfront and milestone payments, in addition to royalties and ot...
CollPlant to Supply rhCollagen to STEMCELL Technologies for Use in a Broad Range of Cell Culture Applications REHOVOT, Israel and VANCOUVER, BC , Dec. 10, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative medicine company, and STEMCELL Technologies, Can...
CollPlant Biotechnologies Reports Third Quarter (Q3) 2020 Financial Results and Provides Business Update - Expanded collaboration agreement with United Therapeutics which exercised its option for 3D bioprinted kidney transplants and $3 million payment to CollPlant - Increase...
News, Short Squeeze, Breakout and More Instantly...
Collplant Holdings Company Name:
CQPTY Stock Symbol:
OTCMKTS Market:
Termination of Licensing Agreement for Bioprinting of Scaffolds for Lung Transplants PR Newswire REHOVOT, Israel , Feb. 25, 2021 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN) a regenerative and aesthetics medicine company, today announced that on ...